Legal Representation
Attorney
Laura R. Wanek
USPTO Deadlines
Next Deadline
3166 days remaining
Section 8 & 9 (20-Year) Renewal Due (Based on registration date 2014-03-11)
Due Date
March 11, 2034
Grace Period Ends
September 11, 2034
Application History
23 events| Date | Code | Type | Description |
|---|---|---|---|
| Nov 5, 2020 | NCS8 | E | NOTICE OF CANCELLATION SEC. 8 EMAILED |
| Nov 4, 2020 | C8.. | O | CANCELLED SEC. 8 (6-YR) |
| May 2, 2020 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| May 2, 2020 | PR23 | O | POST REGISTRATION ACTION MAILED - SEC. 8 & 15 |
| Mar 10, 2020 | E815 | I | TEAS SECTION 8 & 15 RECEIVED |
| Mar 11, 2019 | REM1 | E | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| Mar 11, 2014 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Dec 24, 2013 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Dec 24, 2013 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Dec 4, 2013 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Nov 18, 2013 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Nov 15, 2013 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Nov 12, 2013 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Nov 12, 2013 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Nov 1, 2013 | ALIE | A | ASSIGNED TO LIE |
| Oct 30, 2013 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Sep 13, 2013 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Sep 13, 2013 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Sep 13, 2013 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Sep 6, 2013 | DOCK | D | ASSIGNED TO EXAMINER |
| Jun 4, 2013 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Jun 1, 2013 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| May 24, 2013 | NWAP | I | NEW APPLICATION ENTERED |
Additional Information
Design Mark
The mark consists of the words "NOGRAPHARMA" without a space in between two words. There is a design of two ovals appearing in front of the words.
Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
NOGRA PHARMA